Clinical Trial Update: Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Ravulizumab for Immunoglobulin A Nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Immunoglobulin A Nephropathy, IgAN | Phase 3 | Status: RECRUITING